Parathyroid Carcinoma

  • Ana Luísa Castro Barbosa Faculdade de Medicina da Universidade do Porto
  • João Capela Costa Unidade de Cirurgia Endócrina e Cervical do Serviço de Cirurgia Geral do Hospital São João


Parathyroid carcinoma (PC) is a very rare endocrine tumor, accounting for less than 1% of cases of primary hyperparathyroidism (P-HPT). As in many other tumors, its etiology is unknown, however, mutations in gene HRPT2/CDC73 have recently been found to play a key role in the pathogenesis of this neoplasm. PC is usually a sporadic disease but may occur in the context of genetic syndromes and is reported in patients with secondary hyperparathyroidism. Its diagnosis is a challenge, both clinically and histologically due to the absence of pathognomonic characteristics that allow early distinction between benign and malignant disease. The treatment with the best curative potential is the en bloc resection of the primary tumor with clear margins, so its success depends on the preoperative or intraoperative suspicion of carcinoma. PC has an extended clinical course with multiple recurrences, most of which occur locally, so patients should be monitored for the rest of their lives. Given the limited value of adjuvant therapies, the recommended treatment in cases of recurrence and metastasis is, a surgical resection, whenever possible.


Download data is not yet available.

Author Biographies

Ana Luísa Castro Barbosa, Faculdade de Medicina da Universidade do Porto

Aluna do 6º ano de Medicina da Faculdade de Medicina da Universidade do Porto

João Capela Costa, Unidade de Cirurgia Endócrina e Cervical do Serviço de Cirurgia Geral do Hospital São João

MD MSc, Assistente Hospitalar Graduado da Unidade de Cirurgia Endócrina e Cervical do Serviço de Cirurgia Geral do Hospital São João, Porto, Portugal; Mestre em Medicina Molecular pela Faculdade de Medicina do Porto


1. Cetani F, Pardi E, Marcocci C. Update on parathyroid carcinoma. Journal of endocrinological investigation. 2016;39(6):595-606.
2. Betea D, Potorac I, Beckers A. Parathyroid carcinoma: Challenges in diagnosis and treatment. Annales d'endocrinologie. 2015;76(2):169-77.
3. Do Cao C, Aubert S, Trinel C, Odou MF, Bayaram M, Patey M. Parathyroid carcinoma: Diagnostic criteria, classification, evaluation. Annales d'endocrinologie. 2015;76(2):165-8.
4. Duan K, Mete O. Parathyroid Carcinoma: Diagnosis and Clinical Implications. Turk patoloji dergisi. 2015;31 Suppl 1:80-97.
5. Alperstein A, Bhayani R. Parathyroid carcinoma, a rare cause of primary hyperparathyroidism. BMJ case reports. 2014;2014.
6. Sharretts JM, Kebebew E, Simonds WF. Parathyroid cancer. Seminars in oncology. 2010;37(6):580-90.
7. Wei CH, Harari A. Parathyroid carcinoma: update and guidelines for management. Current treatment options in oncology. 2012;13(1):11-23.
8. Kassahun WT, Jonas S. Focus on parathyroid carcinoma. International journal of surgery. 2011;9(1):13-9.
9. Selvan B, Paul MJ, Seshadri MS, Thomas N, Paul T, Abraham D, et al. High index of clinical suspicion with optimal surgical techniques and adjuvant radiotherapy is critical to reduce locoregional disease progression in parathyroid carcinoma. American journal of clinical oncology. 2013;36(1):64-9.
10. DeLellis RA. Parathyroid tumors and related disorders. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2011;24 Suppl 2:S78-93.
11. Kasaian K, Wiseman SM, Thiessen N, Mungall KL, Corbett RD, Qian JQ, et al. Complete genomic landscape of a recurring sporadic parathyroid carcinoma. The Journal of pathology. 2013;230(3):249-60.
12. Diaconescu MR, Glod M, Costea I, Grigorovici M, Diaconescu S. Clinicopathological phenotype of parathyroid carcinoma: therapeutic and prognostic aftermaths. Chirurgia. 2015;110(1):66-71.
13. Duan K, Gomez Hernandez K, Mete O. Clinicopathological correlates of hyperparathyroidism. Journal of clinical pathology. 2015;68(10):771-87.
14. Adam MA, Untch BR, Olson JA, Jr. Parathyroid carcinoma: current understanding and new insights into gene expression and intraoperative parathyroid hormone kinetics. The oncologist. 2010;15(1):61-72.
15. Rafferty A, England J. Current management of parathyroid tumours. British journal of hospital medicine. 2013;74(1):24-9.
16. Svedlund J, Auren M, Sundstrom M, Dralle H, Akerstrom G, Bjorklund P, et al. Aberrant WNT/beta-catenin signaling in parathyroid carcinoma. Molecular cancer. 2010;9:294.
17. Barazeghi E, Gill AJ, Sidhu S, Norlen O, Dina R, Palazzo FF, et al. 5-Hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma. Clinical epigenetics. 2016;8:31.
18. Kentwell J, Gundara JS, Sidhu SB. Noncoding RNAs in endocrine malignancy. The oncologist. 2014;19(5):483-91.
19. Kumari N, Chaudhary N, Pradhan R, Agarwal A, Krishnani N. Role of Histological Criteria and Immunohistochemical Markers in Predicting Risk of Malignancy in Parathyroid Neoplasms. Endocrine pathology. 2016;27(2):87-96.
20. Zhao J, Hu Y, Liao Q, Niu Z, Xing X, Xia W, et al. Gene identification of potential malignant parathyroid tumors phenotype in Chinese population. Endocrine journal. 2014;61(6):597-605.
21. Al-Kurd A, Mekel M, Mazeh H. Parathyroid carcinoma. Surgical oncology. 2014;23(2):107-14.
22. Mohebati A, Shaha A, Shah J. Parathyroid carcinoma: challenges in diagnosis and treatment. Hematology/oncology clinics of North America. 2012;26(6):1221-38.
23. Butt WT, Azim A, Abbas A, Gauhar TM, Afzal A, Azim KM. Parathyroid carcinoma. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP. 2012;22(9):588-90.
24. Oh MY, Oh SB, Seoung HG, Kim JH, Kim SS, Kim BH, et al. Concurrent parathyroid carcinoma and hyperplasia in hyperparathyroidism. The Korean journal of internal medicine. 2012;27(3):356-9.
25. Schulte KM, Talat N. Diagnosis and management of parathyroid cancer. Nature reviews Endocrinology. 2012;8(10):612-22.
26. Hughes DT, Sorensen MJ, Miller BS, Cohen MS, Gauger PG. The biochemical severity of primary hyperparathyroidism correlates with the localization accuracy of sestamibi and surgeon-performed ultrasound. Journal of the American College of Surgeons. 2014;219(5):1010-9.
27. Whitcroft KL, Sharma A. Sestamibi scintigraphy for parathyroid localisation: a reminder of the dangers of false positives. BMJ case reports. 2014;2014.
28. Dytz MG, Souza RG, Lazaro AP, Goncalves MD, Vidal AP, dos Santos Teixeira Pde F, et al. Parathyroid carcinoma and oxyphil parathyroid adenoma: an uncommon case of misinterpretation in clinical practice. Endocrine journal. 2013;60(4):423-9.
29. Givi B, Shah JP. Parathyroid carcinoma. Clinical oncology. 2010;22(6):498-507.
30. Lang B, Lo CY. Parathyroid cancer. Surgical oncology clinics of North America. 2006;15(3):573-84.
31. Lumachi F, Basso SM, Basso U. Parathyroid cancer: etiology, clinical presentation and treatment. Anticancer research. 2006;26(6C):4803-7.
32. Enomoto K, Uchino S, Ito A, Watanabe S, Shibuya H, Enomoto Y, et al. The surgical strategy and the molecular analysis of patients with parathyroid cancer. World journal of surgery. 2010;34(11):2604-10.
33. Crea N, Pata G, Casella C, Cappelli C, Salerni B. Predictive factors for postoperative severe hypocalcaemia after parathyroidectomy for primary hyperparathyroidism. The American surgeon. 2012;78(3):352-8.
34. Ohe MN, Santos RO, Hojaij F, Neves MC, Kunii IS, Orlandi D, et al. Parathyroid carcinoma and hungry bone syndrome. Arquivos brasileiros de endocrinologia e metabologia. 2013;57(1):79-86.
35. Artinyan A, Guzman E, Maghami E, Al-Sayed M, D'Apuzzo M, Wagman L, et al. Metastatic parathyroid carcinoma to the liver treated with radiofrequency ablation and transcatheter arterial embolization. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(24):4039-41.
36. Clines GA. Mechanisms and treatment of hypercalcemia of malignancy. Current opinion in endocrinology, diabetes, and obesity. 2011;18(6):339-46.
37. Minisola S, Pepe J, Piemonte S, Cipriani C. The diagnosis and management of hypercalcaemia. Bmj. 2015;350:h2723.
38. Reagan P, Pani A, Rosner MH. Approach to diagnosis and treatment of hypercalcemia in a patient with malignancy. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2014;63(1):141-7.
39. Legrand SB. Modern management of malignant hypercalcemia. The American journal of hospice & palliative care. 2011;28(7):515-7.
40. Crowley R, Gittoes N. How to approach hypercalcaemia. Clinical medicine. 2013;13(3):287-90.
41. Bowyer SE, White AM, Ransom DT, Davidson JA. Resistant hypercalcaemia in metastatic parathyroid carcinoma. The Medical journal of Australia. 2013;198(10):559-61.
42. Vellanki P, Lange K, Elaraj D, Kopp PA, El Muayed M. Denosumab for management of parathyroid carcinoma-mediated hypercalcemia. The Journal of clinical endocrinology and metabolism. 2014;99(2):387-90.
43. Horie I, Ando T, Inokuchi N, Mihara Y, Miura S, Imaizumi M, et al. First Japanese patient treated with parathyroid hormone peptide immunization for refractory hypercalcemia caused by metastatic parathyroid carcinoma. Endocrine journal. 2010;57(4):287-92.
44. Barker HS, Podoll MB, Parker JR, Parker JC, Jr., Crim J, Yang X. Parathyroid carcinoma with intracranial metastasis at diagnosis in a patient with uncontrolled hypercalcemia. Annals of clinical and laboratory science. 2014;44(4):484-8.
45. O'Neill CJ, Chan C, Symons J, Learoyd DL, Sidhu SB, Delbridge LW, et al. Parathyroid carcinoma encountered after minimally invasive focused parathyroidectomy may not require further radical surgery. World journal of surgery. 2011;35(1):147-53.
46. McClenaghan F, Qureshi YA. Parathyroid cancer. Gland surgery. 2015;4(4):329-38.
47. Mori H, Okada Y, Arao T, Tanaka Y. Case of parathyroid carcinoma with a highly aggressive clinical course. Journal of UOEH. 2014;36(4):243-9.
48. Tan GC, Shiran MS, Swaminathan M, Phang KS, Rohaizak M. Large retrosternal parathyroid carcinoma with primary hyperparathyroidism. Asian journal of surgery / Asian Surgical Association. 2007;30(4):286-9.
49. Dudney WC, Bodenner D, Stack BC, Jr. Parathyroid carcinoma. Otolaryngologic clinics of North America. 2010;43(2):441-53, xi.
50. Wang O, Wang C, Nie M, Cui Q, Guan H, Jiang Y, et al. Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas. PloS one. 2012;7(9):e45567.
How to Cite
BARBOSA, Ana Luísa Castro; COSTA, João Capela. Parathyroid Carcinoma. Revista Portuguesa de Cirurgia, [S.l.], n. 44, p. 25 - 36, sep. 2018. ISSN 2183-1165. Available at: <>. Date accessed: 03 oct. 2023.
Review Article